Silver Book Fact

Economic value from flu vaccine in elderly

As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest economic benefit.

Molinari, Noelle-Angelique M., Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, et al. The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs. Vaccine. 2007; 25: 5086-96. http://download.thelancet.com/flatcontentassets/H1N1-flu/epidemiology/epidemiology-14.pdf

Reference

Title
The Annual Impact of Seasonal Influenza in the U.S.: Measuring disease burden and costs
Publication
Vaccine
Publication Date
2007
Authors
Molinari, Noelle-Angelique M., Ismael R. Ortega-Sanchez, Mark L. Messonnier, William W. Thompson, Pascale M. Wortley, et al.
Pages
5086-96
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value
  • Future Value

Related Facts

  • Economic value from flu vaccine in elderly
    As over 60% of the economic burden of influenza falls on those ages 65 and older, programs to reduce the impact of influenza on older Americans would have the greatest…  
  • Eradication of infectious diseases from vaccination
    Spanning more than 200 years of research and development, 10 infectious diseases have been at least 90 percent eradicated in the United States thanks to vaccines.  
  • Vaccines in development 2013
    Biopharmaceutical research companies are developing 271 vaccines for infectious diseases, cancer, neurological disorders, allergies, and other diseases.  
  • Savings from flu vaccine
    Vaccination for influenza resulted in an average annual cost savings of $13.66 per healthy working adult vaccinated.  
  • Shingles vaccine reduces incidence by >50%
    Use of a live attenuated VZV (varicella-zoster vaccine) in a randomized trial reduced the incidence of shingles by 51.3%.